2 active not recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow SCLC: new trials by email Literature Review of SCLC trials Research Report on SCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms Topotecan - usual, Topotecan - study - SCLC | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair | 600 | 2026-10-05 | 2026-10-08 |
| PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer PM8002, Paclitaxel, Topotecan - SCLC | Phase 3 | Active not recruiting | Biotheus Inc. | 404 | 2024-11-13 | 2026-10-22 |
Drug Therapy (1) · Paclitaxel (1) · Topotecan (1)
Biotheus Inc. (1) · Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair (1)
China (1) · United States (1)
Caicun Zhou (1) · Haifeng Liu (1)